Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells

Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to specifically transduce APCs is required to promote their translation towards the clinic. We report on the Nanobody (Nb) display technology to target LVs to dendritic cells (DCs) and macrophages. This innovative approach exploits the budding mechanism of LVs to incorporate an APC-specific Nb and a binding-defective, fusion-competent form of VSV.G in the viral envelope. In addition to production of high titer LVs, we demonstrated selective, Nb-dependent transduction of mouse DCs and macrophages both in vitro and in situ. Moreover, this strategy was translated to a human model in which selective transduction of in vitro generated or lymph node (LN)-derived DCs and macrophages, was demonstrated. In conclusion, the Nb display technology is an attractive approach to generate LVs targeted to specific cell types.

• Publication year

  2012

• Venue

  Gene Therapy

• Publication date

  2012-01-12

• Fields of study

  Biology, Medicine, Engineering

• Identifiers
  DOI 10.1038/gt.2011.206PMID 22241177PMCID 3520013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immunotherapy

  2012cited by this paper
• Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immuno Gene Therapy

  2011cited by this paper
• Measles Virus Glycoprotein-Pseudotyped Lentiviral Vector-Mediated Gene Transfer into Quiescent Lymphocytes Requires Binding to both SLAM and CD46 Entry Receptors

  2011cited by this paper
• Lentiviral Vectors Targeted to MHC II Are Effective in Immunization

  2011cited by this paper
• Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus

  2010cited by this paper
• Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types

  2010cited by this paper
• Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

  2010cited by this paper
• HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7

  2010cited by this paper
• Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential

  2010cited by this paper
• Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors.

  2009cited by this paper
• Trophic macrophages in development and disease

  2009cited by this paper
• Single-Chain Antibodies That Target Lentiviral Vectors to MHC Class II on Antigen-Presenting Cells

  2009cited by this paper
• Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity

  2009cited by this paper
• Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.

  2009cited by this paper
• General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold*

  2009cited by this paper
• Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins.

  2008cited by this paper
• Engineered lentivector targeting of dendritic cells for in vivo immunization

  2008cited by this paper
• Insertional mutagenesis and clonal dominance: biological and statistical considerations

  2008cited by this paper
• Lentiviral vectors for anti-tumor immunotherapy.

  2008cited by this paper
• Targeting Lentiviral Vectors to Antigen-Specific Immunoglobulins

  2008cited by this paper
• Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of d-luciferin: effect on intensity, time kinetics and repeatability of photon emission

  2008cited by this paper
• In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance.

  2007cited by this paper
• Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.

  2007cited by this paper
• Activation of Immature Monocyte-Derived Dendritic Cells After Transduction with High Doses of Lentiviral Vectors

  2007cited by this paper
• Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics

  2007cited by this paper
• Tubulovesicular Structures within Vesicular Stomatitis Virus G Protein-Pseudotyped Lentiviral Vector Preparations Carry DNA and Stimulate Antiviral Responses via Toll-Like Receptor 9

  2006cited by this paper
• Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.

  2006cited by this paper
• The effects of N-terminal insertion into VSV-G of an scFv peptide

  2006cited by this paper
• Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors

  2006cited by this paper
• Targeting lentiviral vectors to specific cell types in vivo.

  2006cited by this paper
• Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions.

  2005cited by this paper
• Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy.

  2005cited by this paper
• Nanobodies as novel agents for cancer therapy

  2005cited by this paper
• Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection

  2005cited by this paper
• Targeted retroviral transduction of c-kit+ hematopoietic cells using novel ligand display technology.

  2004cited by this paper
• A novel reticular stromal structure in lymph node cortex: an immuno-platform for interactions among dendritic cells, T cells and B cells.

  2004cited by this paper
• Phosphatidylserine Is Not the Cell Surface Receptor for Vesicular Stomatitis Virus

  2004cited by this paper
• Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells

  2004cited by this paper
• In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.

  2003cited by this paper
• Lentivirally transduced dendritic cells as a tool for cancer immunotherapy

  2003cited by this paper
• The Membrane-Proximal Domain of Vesicular Stomatitis Virus G Protein Functions as a Membrane Fusion Potentiator and Can Induce Hemifusion

  2002cited by this paper
• Lymph node macrophages, but not spleen macrophages, express high levels of unmasked sialoadhesin: implication for the adhesive properties of macrophages in vivo.

  2002cited by this paper
• β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae

  2001cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Naturally occurring antibodies devoid of light chains

  1993cited by this paper
• LSU Digital Commons LSU Digital Commons Altering the tropism of lentiviral vectors through pseudotyping Altering the tropism of lentiviral vectors through pseudotyping

  year unknowncited by this paper

• A Mammalian Surface Display Platform to Optimize the Antigenicity of Viral Proteins for Vaccine Design

  2026cites this paper
• Nanobody-Based Drug Delivery: Emerging Strategies for Targeted Cancer Therapy

  2026cites this paper
• Therapeutic antibody delivery: vector tools to boost efficacy and affordability

  2026cites this paper
• Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors

  2025cites this paper
• Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine

  2025cites this paper
• Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

  2025cites this paper
• Enhancement of lentiviral vectors gene delivery against VEGFR2 expressing cells by co-display of the binding and fusogenic moieties: a two molecules targeting approach

  2025cites this paper
• Nanobody Therapeutics in Alzheimer’s Disease: From Molecular Mechanisms to Translational Approaches

  2025cites this paper
• The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping

  2025cites this paper
• In silico and in vitro evaluation of a PE38 and Nb‐based recombinant immunotoxin targeting the GRP78 receptor in cancer cells

  2024cites this paper
• Assessment of Connexin43 Hemichannel Functionality Based on Cytosolic Uptake of Yo-Pro1.

  2024cites this paper
• Lentiviral Vectors as a Vaccine Platform against Infectious Diseases

  2023cites this paper
• Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine

  2023cites this paper
• Construction of a T7 phage display nanobody library for bio-panning and identification of chicken dendritic cell-specific binding nanobodies

  2022cites this paper
• Emerging applications of nanobodies in cancer therapy.

  2022cites this paper
• Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development

  2022cites this paper
• An Update on the HIV DNA Vaccine Strategy

  2021cites this paper
• Nanobody: a promising toolkit for molecular imaging and disease therapy

  2021cites this paper
• Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential

  2021cites this paper
• Imaging the cellular components of the immune system for advancing diagnosis and immunotherapy of cancers

  2021cites this paper
• Novel 3D Lung Tumor Spheroids for Oncoimmunological Assays

  2021cites this paper
• A comprehensive comparison between camelid nanobodies and single chain variable fragments

  2021cites this paper
• Use of lentiviral vectors in vaccination

  2021influential citation
• Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade

  2021cites this paper
• Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications

  2021cites this paper
• Improvements in drug delivery and monitoring of diseases in biotherapeutics

  2020cites this paper
• Single-Domain Antibodies: Biology, Engineering and Emerging Applications

  2020cites this paper
• Nanobodies in cancer.

  2020cites this paper
• Theranostics in immuno-oncology using nanobody derivatives

  2019cites this paper
• Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors

  2019cites this paper
• Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer

  2019cites this paper
• Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations.

  2019cites this paper
• The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

  2018cites this paper
• Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes

  2018cites this paper
• Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy

  2017influential citation
• Development of an adenovirus vector vaccine platform for targeting dendritic cells

  2017cites this paper
• Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery

  2017cites this paper
• Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy

  2017cites this paper
• Unraveling Antibody Display: Systems Biology and Personalized Medicine.

  2017cites this paper
• Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-Derived Suppressor Cells

  2016cites this paper
• Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.

  2016cites this paper
• Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon

  2016cites this paper
• Recent Advances in Lentiviral Vaccines for HIV-1 Infection

  2016cites this paper
• Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy

  2016cites this paper
• Myeloid-Derived Suppressor Cells and Cancer

  2016cites this paper
• Nanobodies as therapeutics: big opportunities for small antibodies.

  2016cites this paper
• Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model

  2015cites this paper
• The transduction pattern of IL‐12‐encoding lentiviral vectors shapes the immunological outcome

  2015cites this paper
• Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer

  2015cites this paper
• Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

  2015cites this paper
• Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology

  2015cites this paper
• Expression of a biotin acceptor peptide-containing protein with potential incorporation on the lentiviral envelope as a viral surface engineering platform

  2015cites this paper
• Immunization of Mice with Lentiviral Vectors Targeted to MHC Class II+ Cells Is Due to Preferential Transduction of Dendritic Cells In Vivo

  2014cites this paper
• Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL.

  2014cites this paper
• Immunogenicity of targeted lentivectors

  2014cites this paper
• Alginate-coated chitosan nanogels differentially modulate class-A and class-B CpG-ODN targeting of dendritic cells and intracellular delivery.

  2014cites this paper
• Preferential Lentiviral Targeting of Astrocytes in the Central Nervous System

  2013cites this paper
• Targeting of Human Antigen-Presenting Cell Subsets

  2013cites this paper
• Targeted Lentiviral Vectors: Current Applications and Future Potential

  2013cites this paper
• Application and the research progress of nanobodies

  2013cites this paper
• Lentiviral vectors: a versatile tool to fight cancer.

  2013cites this paper
• Nanobodies and their potential applications.

  2013cites this paper
• Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer.

  2012cites this paper
• Dendritic Cell-Directed Vaccination with a Lentivector Encoding PSCA for Prostate Cancer in Mice

  2012cites this paper
• Specific Targeting of Human Interleukin (IL)-13 Receptor α2-Positive Cells with Lentiviral Vectors Displaying IL-13

  2012cites this paper
• A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

  2012cites this paper
• Microenvironment and Immunology Proin fl ammatory Characteristics of SMAC / DIABLO-Induced Cell Death in Antitumor Therapy

  2012cites this paper
• A novel antiviral approach.

  2012cites this paper
• Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy.

  2012cites this paper